AGL 40.85 Decreased By ▼ -0.65 (-1.57%)
AIRLINK 130.00 Increased By ▲ 2.00 (1.56%)
BOP 6.55 Increased By ▲ 0.29 (4.63%)
CNERGY 4.03 Decreased By ▼ -0.10 (-2.42%)
DCL 8.57 Increased By ▲ 0.13 (1.54%)
DFML 41.50 Increased By ▲ 0.81 (1.99%)
DGKC 86.80 Decreased By ▼ -1.10 (-1.25%)
FCCL 33.39 Decreased By ▼ -0.71 (-2.08%)
FFBL 65.85 Decreased By ▼ -0.48 (-0.72%)
FFL 10.45 Decreased By ▼ -0.11 (-1.04%)
HUBC 110.30 Increased By ▲ 1.60 (1.47%)
HUMNL 15.27 Increased By ▲ 0.81 (5.6%)
KEL 4.84 Increased By ▲ 0.19 (4.09%)
KOSM 7.86 Increased By ▲ 0.53 (7.23%)
MLCF 42.05 Decreased By ▼ -0.67 (-1.57%)
NBP 61.00 Increased By ▲ 0.16 (0.26%)
OGDC 182.70 Increased By ▲ 3.73 (2.08%)
PAEL 25.35 Decreased By ▼ -0.35 (-1.36%)
PIBTL 6.26 Increased By ▲ 0.20 (3.3%)
PPL 147.50 Increased By ▲ 1.35 (0.92%)
PRL 24.52 Decreased By ▼ -0.39 (-1.57%)
PTC 16.19 Increased By ▲ 0.05 (0.31%)
SEARL 70.61 Increased By ▲ 0.41 (0.58%)
TELE 7.31 Increased By ▲ 0.09 (1.25%)
TOMCL 36.22 Increased By ▲ 0.02 (0.06%)
TPLP 7.85 Increased By ▲ 0.01 (0.13%)
TREET 15.39 Decreased By ▼ -0.20 (-1.28%)
TRG 51.80 Increased By ▲ 1.44 (2.86%)
UNITY 27.05 Increased By ▲ 0.15 (0.56%)
WTL 1.23 Decreased By ▼ -0.01 (-0.81%)
BR100 9,838 Increased By 43.3 (0.44%)
BR30 29,994 Increased By 347.1 (1.17%)
KSE100 92,561 Increased By 539.3 (0.59%)
KSE30 28,777 Increased By 112.5 (0.39%)

Germany's Bayer sees the current credit crisis as an opportunity to buy assets at favourable prices that can fuel future growth in its key healthcare division. Healthcare head Arthur Higgins said he wouldn't rush to strike deals before the dust had settled on "the new world order" but he was confident the group's healthy cash and credit position meant it would emerge a winner.
"We see this as an opportunity and we would hope to be able to take advantage of that opportunity in the next three to 24 months," he said in a telephone interview from Brussels.
"We are committed to looking at ways to expand our healthcare business inorganically. We believe that we are better positioned than many of our competitors." The main targets for acquisitions would be non-pharmaceutical businesses designed to expand Bayer's existing operations in over-the-counter (OTC) medicines, medical devices, diabetes care and animal health products.
But Bayer could also snap up companies developing prescription drugs, if the fit was right.
Bayer has been more successful than many of its larger rivals in getting new drugs to market.
Its biggest new product hope, the anticoagulant Xarelto, was launched in Britain and Germany on and is tipped by the company to be a potential 2 billion-euros-a-year ($2.8 billion) seller.
It also has a number of products in development that could become big sellers, including a product known as VEGF-trap for sight loss, Campath for multiple sclerosis and a Phase II drug for pulmonary arterial hypertension, for which clinical trial results will be announced this weekend. "We expect our pharma business to grow at least in line with the pharma market this year and next and accelerate thereafter, so we will grow above the market," Higgins said.
Similar above-market growth rates are seen for OTC medicines and the other non-pharma operations. The German chemicals-and-pharmaceuticals hybrid's enviable new product line-up and limited exposure to generic competition has made it a subject of bid speculation, with Pfizer frequently rumoured as a possible acquirer.
Many industry analysts, however, are dubious of the strategic fit between the two companies - particularly as buying Bayer would land Pfizer with a raft of non-core chemicals assets.

Copyright Reuters, 2008

Comments

Comments are closed.